Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 18, 2017 - Issue 12
Submit an article Journal homepage
378
Views
6
CrossRef citations to date
0
Altmetric
Drug Evaluation

Valbenazine for the treatment of tardive dyskinesia

Lauren C. SeebergerDepartment of Neurology, University of Colorado, Denver, CO, USACorrespondence[email protected]
View further author information
&
Robert A. HauserDepartment of Neurology, University of South Florida, Tampa, FL, USAView further author information
Pages 1279-1287 | Received 10 Feb 2017, Accepted 05 Jul 2017, Published online: 02 Aug 2017

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Daniel O. Claassen, Michael Philbin & Benjamin Carroll. (2019) Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington’s disease: a review of clinical trial data. Expert Opinion on Pharmacotherapy 20:18, pages 2209-2221.
Read now

Articles from other publishers (5)

Qilin Liang, Dongmei Wang, Huixia Zhou, Dachun Chen, Meihong Xiu, Lixia Cui & Xiangyang Zhang. (2022) Tardive dyskinesia in Chinese patients with schizophrenia: Prevalence, clinical correlates and relationship with cognitive impairment. Journal of Psychiatric Research 151, pages 181-187.
Crossref
Farwa Ali & Eelco F. Wijdicks. (2019) Treatment of Movement Disorder Emergencies in Autoimmune Encephalitis in the Neurosciences ICU. Neurocritical Care 32:1, pages 286-294.
Crossref
Nicki Niemann & Joohi Jimenez-Shahed. (2019) Deutetrabenazine in the treatment of tardive dyskinesia. Neurodegenerative Disease Management 9:2, pages 59-71.
Crossref
Nicki Niemann & Joseph Jankovic. (2018) Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs 78:5, pages 525-541.
Crossref
Katharina Stegmayer, Sebastian Walther & Peter van Harten. (2018) Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies. CNS Drugs 32:2, pages 135-147.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.